Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F18%3AE0107319" target="_blank" >RIV/00843989:_____/18:E0107319 - isvavai.cz</a>

Výsledek na webu

<a href="https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-018-0788-7" target="_blank" >https://cardiab.biomedcentral.com/track/pdf/10.1186/s12933-018-0788-7</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s12933-018-0788-7" target="_blank" >10.1186/s12933-018-0788-7</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?

Popis výsledku v původním jazyce

Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be 'silent' or 'asymptomatic', but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anticipated that patients will receive an earlier diagnosis and appropriate and timely treatment. Given the availability of anti-diabetic medications that have been shown to concomitantly reduce CV risk and mortality, it is imperative to improve early identification and initiate treatment as soon as possible in order to enable as many patients with T2D as possible to benefit.

Název v anglickém jazyce

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?

Popis výsledku anglicky

Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be 'silent' or 'asymptomatic', but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anticipated that patients will receive an earlier diagnosis and appropriate and timely treatment. Given the availability of anti-diabetic medications that have been shown to concomitantly reduce CV risk and mortality, it is imperative to improve early identification and initiate treatment as soon as possible in order to enable as many patients with T2D as possible to benefit.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cardiovascular diabetology

ISSN

1475-2840

e-ISSN

—

Svazek periodika

17

Číslo periodika v rámci svazku

145

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

1-6

Kód UT WoS článku

000450904500001

EID výsledku v databázi Scopus

2-s2.0-85056977005